Study on the expression of TOP2A in hepatocellular carcinoma and its relationship with patient prognosis

• Published in: Cancer cell international Vol. 22; no. 1; p. 29
• Main Authors: Meng, Jiali, Wei, Yuanchao, Deng, Qing, Li, Ling, Li, Xiaolong
• Format: Journal Article
• Language: English
• Published: England BioMed Central 15.01.2022; BMC
• Subjects: Bioinformatics; Biomarkers; Cell cycle; Datasets; Gene expression; Genomics; HCC; Hepatocellular carcinoma; Immunohistochemical test; Immunohistochemistry; Liver cancer; Medical prognosis; Mutation; Pathogenesis; Patients; Primary Research; Prognosis; Proteins; Software; Survival analysis; Therapeutic targets; TOP2A; Tumors; TOP2A; HCC; Bioinformatics; Immunohistochemical test
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-021-02439-0

Hepatocellular carcinoma (HCC) is a primary liver cancer with a high mortality rate. However, the molecular mechanism of HCC formation remains to be explored and studied. To investigate the expression of TOP2A in hepatocellular carcinoma (HCC) and its prognosis. The data set of hepatocellular carcinoma was downloaded from GEO database for differential gene analysis, and hub gene was identified by Cytoscape. GEPIA was used to verify the expression of HUB gene and evaluate its prognostic value. Then TOP2A was selected as the research object of this paper by combining literature and clinical sample results. Firstly, TIMER database was used to study TOP2A, and the differential expression of TOP2A gene between normal tissues and cancer tissues was analyzed, as well as the correlation between TOP2A gene expression and immune infiltration of HCC cells. Then, the expression of top2a-related antibodies was analyzed using the Human Protein Atlas database, and the differential expression of TOP2A was verified by immunohistochemistry. Then, SRTING database and Cytoscape were used to establish PPI network for TOP2A and protein-protein interaction analysis was performed. The Oncomine database and cBioPortal were used to express and identify TOP2A mutation-related analyses. The expression differences of TOP2A gene were identified by LinkedOmics, and the GO and KEGG pathways were analyzed in combination with related genes. Finally, Kaplan-Meier survival analysis was performed to analyze the clinical and prognosis of HCC patients. TOP2A may be a new biomarker and therapeutic target for hepatocellular carcinoma.